update: proposed treatment and status


These are notes from Prof. Baum in Germany. I think it helps explain the current condition and proposed treatment regimen better than I can.

"Anthony has several extremely hypermetabolic (FDG-avid) lesions, which usually is a sign of tumor aggressiveness. Therefore he has – according to the new NANETS/WHO classification of 2010 (see attached) – a so called mixed neuroendocrine carcinoma (see page 609) which was also confirmed by the immunohistochemical studies we have performed on his primary tumor in the pancreas tail and the liver mets."

"I proposed to him yesterday exactly TEMODAR+XELODA for chemo (A more aggressive alternative (if this combination fails) would be Cisplatin+Etoposid.)"

"However, one could try first SUTENT for 4 weeks (approved for pancreatic NET in Europe) or NEXAVAR (Sorafenib) or AFINITOR (Everolimus), then repeat the FDG-PET/CT and measure the metabolic response to the treatment with one of the kinase inhibitors. If it fails, then persue with TEM+XEL, if it works we would do follow up every 3 to 6 months. 5-FU alone is not effective in our experience."

"Actually the Ga-68 DOTATOC SMS receptor PET/CT (done yesterday) showed that there was obviously a very good response of the differentiated metastases as the somatostatin receptor positive lesions have nearly gone (there are only few weakly positive lesions seen in the residual liver and there are no extrahepatic sites)."

"I suggest that he has in addition a EUS (eventually with biopsy) with special focus on the pancreas head/corpus as the FGD-PET/CT shows a very hypermetabolic lesion in this region (attributed as “aortocaval lymph node” in the PET/CT report) which could, however, also be a second primary tumor in the pancreas."

Comments

Popular posts from this blog

Tickets to Germany: Bad Berka

...a long winded story not written all that well.

On the refrigerator...